Capricor files BLA for deramiocel in DMD cardiomyopathy; reports ~$85M cash as of Sept 30

CAPRICOR THERAPEUTICS, INC.

BLA for deramiocel filed Oct 2024 seeking full approval for DMD cardiomyopathy; full submission by year-end 2024.
HOPE-2/OLE data vs natural history supports BLA; HOPE-3 Cohorts A+B combined as post-approval study, Cohort A unblinding paused.
StealthX SARS-CoV-2 vaccine selected for Project NextGen; manufacturing ongoing, delivery to NIAID by end-2024.
Private placement to Nippon Shinyaku: 2.8M shares at $5.36 for ~$15M; ATM sales: 5.5M shares at $9.84 avg for ~$53.9M.
Preliminary cash balance ~$85M as of Sept 30, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.